EXPRESSION OF ICAM-1, VCAM-1, L-SELECTIN, AND LEUKOSIALIN IN THE MOUSE CENTRAL-NERVOUS-SYSTEM DURING THE INDUCTION AND REMISSION STAGES OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS

Citation
Jm. Dopp et al., EXPRESSION OF ICAM-1, VCAM-1, L-SELECTIN, AND LEUKOSIALIN IN THE MOUSE CENTRAL-NERVOUS-SYSTEM DURING THE INDUCTION AND REMISSION STAGES OF EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS, Journal of neuroimmunology, 54(1-2), 1994, pp. 129-144
Citations number
44
Categorie Soggetti
Neurosciences,Immunology
Journal title
ISSN journal
01655728
Volume
54
Issue
1-2
Year of publication
1994
Pages
129 - 144
Database
ISI
SICI code
0165-5728(1994)54:1-2<129:EOIVLA>2.0.ZU;2-6
Abstract
Adhesion molecules facilitate infiltration of leukocytes into the cent ral nervous system (CNS) of mice with experimental allergic encephalom yelitis (EAE). Expression of the adhesion molecules ICAM-1 (CD54), VCA M-1 (CD106), L-selectin (CD62L), and leukosialin (CD43) was analyzed v ia immunocytochemistry 4-28 days after the injection of encephalitogen into EAE-susceptible SWXJ mice. Constitutive ICAM-1 expression on lar ge-diameter CNS vessels was upregulated on post-injection days 8, 11, 14 and 18 (concurrent with de novo expression on smaller capillaries a nd glial cells), partially downregulated by day 23, and back to contro l levels by day 28. Constitutive VCAM-1 expression was upregulated by day 14 and back to control levels by day 28. Upregulation of ICAM-1 te mporally coincided with the immigration of CD4(+) lymphocytes and L-se lectin(+) leukocytes into the CNS, while downregulation coincided with their emigration. The infiltration of CD43(+) leukocytes also coincid ed with the upregulation of vascular adhesion molecules, but CD43(+) c ells remained in the CNS after ICAM-1 and VCAM-1 had returned to contr ol levels. Cellular infiltration and adhesion-molecule expression prec eded EAE clinical symptoms by a minimum of 3 days, suggesting a causal role of adhesion molecules in the initiation of CNS inflammation. How ever, prophylactic injections of monoclonal antibodies against either ICAM-1, L-selectin, or CD43, did not ameliorate the clinical severity of EAE in this model.